Guidelines for the Management of Occupational Exposures to HBV, HCV, and HIV and Recommendations for Postexposure Prophylaxis



Similar documents
Managing Bloodborne Pathogens Exposures

Exposure. What Healthcare Personnel Need to Know

When an occupational exposure occurs, the source patient should be evaluated for both hepatitis B and hepatitis C. (AII)

POST-EXPOSURE PROPHYLAXIS IN THE HEALTH CARE SETTING

Body Fluid Exposure:

Bloodborne Pathogens (HIV, HBV, and HCV) Exposure Management

Post-Exposure Prophylaxis

Title: Post Exposure Prophylaxis Page 1 of 8 Policy No: 1 CLN 010 Effective Date 04/15/11

12/2/2015 HEPATITIS B AND HEPATITIS C BLOOD EXPOSURE OBJECTIVES VIRAL HEPATITIS

POSTEXPOSURE PROPHYLAXIS

OCCUPATIONAL HEALTH, DISABILITY AND LEAVE SECTOR MEASURES TO MINIMIZE EXPOSURE TO BLOODBORNE PATHOGENS AND POST-EXPOSURE PROPHYLAXIS POLICY

Appendix 3 Exposure Incident Report Form

Didactic Series. Updated Post-Exposure Prophylaxis (PEP) Guidelines. Daniel Lee, MD UCSD Medical Center, Owen Clinic January 9, 2014

Guidelines for Managing Exposures to Blood Borne Pathogens

MUSC Occupational Blood Borne Pathogen Protocol Off-Campus Procedure Packet

OCCUPATIONAL SAFETY AND HEALTH ADMINISTRATION (OSHA)

POST-EXPOSURE PROPHYLAXIS IN THE HEALTH CARE SETTING

Integrated Post-exposure Protocol for HIV, HBV and HCV: Guidelines for Managing Exposures to Blood and Body Fluids

Burton Hospitals NHS Foundation Trust. Corporate / Directorate. Clinical / Non Clinical. Department Responsible for Review:

A P P E N D I X SAMPLE FORMS

POST EXPOSURE MANAGEMENT: HEPATITIS B, HEPATITIS C AND HIV

GUIDELINES FOR THE MANAGEMENT OF A PERCUTANEOUS OR SEXUAL EXPOSURE TO BLOODBORNE PATHOGENS DEPARTMENT OF HEALTH AND WELLNESS PRINCE EDWARD ISLAND

OSHA s Bloodborne Pathogens Standard

Needle-Stick Policy.

Roger Williams University. Bloodborne Pathogens Exposure Control Plan

Revised February 5, 2014

Protocol for Needle Stick Injuries Occurring to NY Medical College Students In Physicians Offices

Instructions for Abroad Clinical Rotation

HIV, Hepatitis B and Hepatitis C - Management of Health Care Workers Potentially Exposed

BLOOD AND BODY FLUID EXPOSURE MANAGEMENT TOOL

DISEASES SPREAD THROUGH BLOOD AND BODY FLUIDS

Prevention of transmission of HIV and other bloodborne viruses in healthcare and post exposure prophylaxis. John Ferguson, UPNG 2012

(C) Deep injury and those caused by hollow bore needles, where more potential transference of blood is involved.

PEP Step 2: Report and Document

Instructions for Clinical Rotation Abroad

AUBURN UNIVERSITY HARRISON SCHOOL OF PHARMACY

POST-EXPOSURE PROPHYLAXIS (HIV, HEP B, HEP C)

OUTLINE POST EXPOSURE PROPHYLAXIS (PEP) OCCUPATIONAL RISK OF VIRAL TRANSMISSION WITH SHARP INJURY FROM INFECTED SOURCE:

Bloodborne Pathogens. Scott Anderson CCEMTP. Materials used with permission from the Oklahoma State University

POLICY 08:18:00 BLOODBORNE PATHOGENS CONTROL PLAN

WHY ARE WE HERE? OSHA BB Pathogen standard. The more you know, the better you will perform in real situations!

UCSF Communicable Disease Surveillance and Vaccination Policy

William Atkinson, MD, MPH Hepatitis B Vaccine Issues June 16, 2016

Bloodborne Pathogens Program Revised July,

Bloodborne Pathogens (BBPs) Louisiana Delta Community College

Synopsis from the ASA Recommendations for Infection Control for the Practice of Anesthesiology (Third Edition, 2011)*

Biohazard - Anything that is harmful or potentially harmful to man, other species or the environment.

HEPATITIS A, B, AND C

Medical Management of Exposures: HIV, HBV, HCV, Human Bites, and Sexual Assaults

FLORENCE TOWNSHIP BOARD OF EDUCATION FILE CODE: / Florence, New Jersey

PREVENTION AND MANAGEMENT OF EXPOSURE TO HEALTHCARE ASSOCIATED INFECTIONS (INCLUDING HEPATITIS B AND C) POLICY

Commonly Asked Questions About Chronic Hepatitis C

4/15/2010. Vermont Department of Health STD/HIV Program Vermont Department of Health STD/HIV Program. Vermont Department of Health STD/HIV Program

6.0 Infectious Diseases Policy: Student Exposure Control Plan

Guideline for the management of occupational exposure to blood and body fluids

OCCUPATIONAL EXPOSURE TO BLOODBORNE PATHOGENS (29 CFR )

Bloodborne Exposure Incident Report -Questionnaire and Report-

HIV/AIDS: General Information & Testing in the Emergency Department

ROYAL HOSPITAL FOR WOMEN

Environmental Health and Safety Offices BLOODBORNE PATHOGENS

Health Care Worker Health and Safety: Preventing Needlestick Injury and Occupational Exposure to Bloodborne Pathogens

UWHC GME Global Health Emergency Plan

Therapeutic Guidelines. Accidental exposure guidelines

NON-OCCUPATIONAL POST EXPOSURE PROPHYLAXIS FOR SEXUAL ASSAULT SURVIVORS. Carl LeBuhn, MD

HEPATITIS WEB STUDY Acute Hepatitis C Virus Infection: Epidemiology, Clinical Features, and Diagnosis

Mock OSHA Inspection:

Infection Prevention and Control Policy Prevention and Management of Occupational Exposure to Blood-Borne Viruses (BBVs) and Post-Exposure Prophylaxis

Canberra Hospital and Health Services Clinical Procedure Blood Borne Virus: Occupational Risk Exposure Management

Bloodborne Pathogens. San Diego Unified School District Nursing & Wellness Program August 2013

Bloodborne Pathogens. Updated

HIV Post Exposure Prophylaxis Update

NON-OCCUPATIONAL POST EXPOSURE PROPHYLAXIS (npep)

SHARPS INJURY POLICY

Knowledge about Post-exposure Prophylaxis for Hepatitis B Virus among Dentists and Dental Students in Pakistan

EXPOSURE CONTROL PLAN (sample) 1 Child Care Directors and Employers

Preface. TTY: (888) or Hepatitis C Counseling and Testing, contact: 800-CDC-INFO ( )

Blood Borne Pathogen Exposure Control Plan Checklist

Hilgaard F Visser MBChB Senior Registrar Department Orthopaedic Surgery, University of Pretoria

This pamphlet describes how all school employees, regardless of job assignment, can minimize the risk of exposure to viral hepatitis.

WEST VIRGINIA UNIVERSITY EXPOSURE CONTROL PLAN FOR NON-HOSPITAL PERSONNEL

July 3, III. VA policy:

Guidelines for. Blood-borne Pathogen Exposure and Post-Exposure Prophylaxis in Global Health Field Sites

UNIVERSITY OF KENTUCKY HEALTH CARE COLLEGES POLICY ON EDUCATIONAL EXPOSURE TO BLOOD BORNE PATHOGENS

DO YOU WORK AROUND BLOOD OR BODY FLUIDS? Cal/OSHA s New Rules

Blood borne Pathogens

Exposure Control Plan Bloodborne Infectious Diseases

SECTION SEVEN INSTITUTIONAL POLICIES RELATIVE TO GME PROGRAMS POLICY NO: 7. 6 SUBJECT: EMPLOYEE HEALTH SERVICE PROCEDURES AND GUIDELINES

Blood/Bodily Fluid Exposure and Needlestick Injury Policy Statement & HIV PEP Kit Dispensing Guideline

UPDATE IN HIV POST-EXPOSURE PROPHYLAXIS. Weerawat Manosuthi

Hepatitis B Virus (Pregnancy) Investigation Guideline

Patient Information Sheet

GUIDE TO FOLLOW UP TESTING FOR BLOOD OR BODY FLUID EXPOSURES AND NEEDLESTICK INJURIES

Definitions. This plan. membrane, These are. additions and. and. weeping a source of. withstand the. demands of to or from a

MICHIGAN RECOMMENDATIONS HIV, HEPATITIS B, AND HEPATITIS C-INFECTED HEALTH CARE WORKERS

Reference:

THE A, B, C S OF HEPATITIS. Matt Eidem, M.D. Digestive Health Associates of Texas 1600 Coit Road Suite #301 Plano, Texas (972)

Management Plan For Control of Blood-borne Pathogens, Infectious Wastes and Other Potentially Hazardous Biological Agents

160S01105, Page 1 of 7. Human Hepatitis B Immunoglobulin, solution for intramuscular injection.

Viral Hepatitis A, B, and C

The New OSHA Regulations on. Sharps Safety Requirements

Transcription:

Guidelines for the Management of Occupational Exposures to HBV, HCV, and HIV and Recommendations for Postexposure Prophylaxis

Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), and Human Immunodeficiency Virus (HIV) Bloodborne viruses Can produce chronic infection Transmissible in healthcare settings

Preventing Transmission of Bloodborne Viruses in Healthcare Settings Promote hepatitis B vaccination Treat all patients as potentially infectious Use barriers to prevent blood/body fluid contact Prevent percutaneous injuries

Preventing Percutaneous Injuries Eliminating unnecessary needle use Using devices with safety features Developing safe work practices for handling needles and other sharp devices Safely disposing of sharps and blood-contaminated materials

Factors Influencing Occupational Risk of Bloodborne Virus Infection Prevalence of infection among patients Type of exposure and type of virus Nature and frequency of blood exposures

Prevalence of Bloodborne Virus Infection in Patients Generally higher in hospitalized patients than general population Varies with geographic area Varies with patient risk factors (injecting drug use, multiple sex partners)

Risk of HBV, HCV and HIV Transmission after Occupational Percutaneous Exposure HBV risk varies depending on e-antigen status of source person If e-antigen positive, risk is up to 30% If e-antigen negative, risk is 1-6% HCV risk is 1.8% (range of 0-7%) HIV risk is 0.3% (range of 0.2-0.5%)

Frequency of Percutaneous Injury in US Healthcare Personnel 384,325 annually (about 1000 per day) percutaneous injuries are sustained by healthcare personnel in US hospitals* The number of injuries sustained outside of hospital settings is unknown Frequency of percutaneous injury varies by occupation and healthcare setting * Panlilio, AL, et. al. Estimate of the Annual Number of Percutaneous Injuries in U.S. Healthcare Workers. 4th Decennial Conference, March 5-9, 2000

Exposure Types for Blood/Body Fluid Exposures* June 1995-December 2000 (n=12,678) Mucous membrane 1817 (14%) Non-intact skin 352 (3%) Bite 131 (1%) Percutaneous 10,378 (82%)

Device Types for Percutaneous Injuries June 1995-December 2000 (n=10,378) Hollow-bore needle (60%) Glass (2%) Other/ unknown (6%) Solid sharp (32%) Suture needle (17%) Scalpel (7%) Other (8%)

Postexposure Management Clear policies/procedures Confidentiality of exposed and source persons Management of exposures Posted in visible place Training of healthcare personnel Rapid access to clinical care postexposure prophylaxis (PEP) testing of source patients/exposed persons Injury prevention assessment

Elements of Postexposure Management Wound management Exposure reporting Assessment of infection risk type and severity of exposure bloodborne infection status of source person Appropriate treatment, follow-up, and counseling

Postexposure Management: Wound Care Clean wounds with soap and water Flush mucous membranes with water No evidence of benefit for: application of antiseptics or disinfectants squeezing ( milking ) puncture sites Avoid use of bleach and other agents

Postexposure Management: The Exposure Report Date and time of exposure Procedure details what, where, how, with what device Exposure details...route, body substance involved, volume/duration of contact Information about source person and exposed person

Postexposure Management: Assessment of Infection Risk Type of exposure Body substance percutaneous mucous membrane non-intact skin bites resulting in blood exposure blood bloody fluid Semen, vaginal secretions, CSF, pleural, peritoneal, pericardial, amniotic

Postexposure Management: Assessment of Infection Risk Source person presence of HBsAg presence of HCV antibody presence of HIV antibody

Postexposure Management: Unknown or Untestable Source Consider information about exposure where and under what circumstances prevalence of HBV, HCV, or HIV in the population group Testing of needles and other sharp instruments NOT RECOMMENDED unknown reliability and interpretation of findings hazard of handling sharp instrument

Postexposure Management: Evaluating the Source Informed consent should be obtained in accordance with state and local laws Confidentiality of the source person

Occupational HBV Exposures

Concentration of HBV in Body Fluids High Moderate Low/Not Detectable Blood Semen Urine Serum Vaginal Fluid Feces Wound exudates Saliva Sweat Tears Breast Milk

Elements of Postexposure Management: HBV Baseline evaluation and testing of exposed person with unknown HBV immune status Consideration of treatment when to give what to give Follow-up testing and counseling

Postexposure Management: Baseline HBV Testing of Exposed* Person Test for anti-hbs if person has been vaccinated, but vaccine response is unknown Baseline testing not necessary if vaccine response is known If exposed person has been vaccinated and is a known responder to the vaccine, no PEP is necessary

Recommended Postexposure Management: PEP for Exposure to HBV Unvaccinated HBIG x 1 and initiate hepatitis B vaccine series Previously vaccinated Antibody response unknown Test exposed person for anti-hbs 1. If adequate, no treatment 2. If inadequate, HBIG x 1 and vaccine booster

Side Effects of Hepatitis B Vaccine Pain at injection site Mild to moderate fever Anaphylaxis in an estimated 1 in 600,000 doses given No serious adverse events detected through surveillance No risk of adverse effects to fetus

Efficacy of HBV PEP * Regimen Multiple doses of HBIG alone when 1st dose initiated within 1 week Hepatitis B vaccine series alone Combination of HBIG and vaccine series Prevention of HBV Infection 70-75% 70-75% 85-95%

Hepatitis B Vaccine: Long-Term Efficacy Anti-HBs titers decline to <10 miu/ml in 30-50% of adults within 8-10 years after vaccination Exposure to HBV results in anamnestic anti-hbs response that prevents clinically significant HBV infection Immune memory remains intact for at least 20 years after immunization Chronic HBV infection rarely documented among vaccine responders Booster doses currently not recommended

Postexposure Management: Follow-up HBV Testing of Exposed Person Perform follow-up anti-hbs testing in healthcare personnel who receive hepatitis B vaccine test for anti-hbs 1-2 months after last dose anti-hbs response to vaccine cannot be ascertained if HBIG received in the previous 3-4 months

Postexposure Management: HBV Postexposure Counseling Refrain from donating blood, plasma, organs, tissue, or semen. No need for: modification of sexual practices or refraining from becoming pregnant or breastfeeding modification to patient care responsibilities for exposed person If acute HBV infection, evaluate according to published recommendations

Occupational HCV Exposures

Occupational Transmission of HCV Inefficiently transmitted by occupational exposures Average incidence 1.8% (range 0-7%) following percutaneous exposure from HCV-positive source Case reports of transmission from blood splash to mucous membrane Prevalence 1-2% among healthcare personnel Lower than among adults in the general population 10 times lower than for HBV infection

Elements of Postexposure Management: HCV Baseline evaluation and testing Follow-up testing and counseling PEP Not recommended after exposure immunoglobulin not effective no data on use of antivirals (e.g., interferon), and may be effective only with established infection antivirals not FDA approved for this setting

Postexposure Management: Baseline HCV Testing of Exposed Person If HCV-positive source, test exposed person for anti-hcv and ALT If source not infected, baseline testing not necessary

Postexposure Management: HCV Postexposure Counseling Refrain from donating blood, plasma, organs, tissue, or semen. No need for: modification of sexual practices or refraining from becoming pregnant special precautions to prevent secondary transmission. modification to patient care responsibilities for exposed person, even if HCV infected

Occupational HIV Exposures

Occupations of US Healthcare Personnel with Documented/Possible Occupational AIDS/HIV Infection Documented Possible Occupation Transmission (No.) Transmission ( No.) Nurse 24 34 Laboratory technician, clinical 16 17 Physician, nonsurgical 6 12 Health aide/attendant 1 15 Housekeeper/maintenance worker 2 13 Emergency medical technician/paramedic ---- 12 Dental worker, including dentist ---- 6 Laboratory technician, nonclinical 3 ---- Physician, surgical ---- 6 Respiratory therapist 1 2 Embalmer/morgue technician 1 2 Technician, dialysis 1 3 Technician, surgical 2 2 Technician/therapist, other than above ---- 9 Other healthcare occupations ---- 4 Total 57 137

Details of the 57 Exposures Resulting in Occupational HIV Transmission Percutaneous 48 Unknown 2 Both 2 Mucous membrane 5

Average Risk of HIV Infection to Healthcare Personnel by Exposure Route Percutaneous 0.3% Mucous membrane 0.09% Non-intact skin <0.1%

Risk Factors for HIV Transmission After Percutaneous Exposure to HIV-Infected Blood: Risk Factor Adjusted Odds ratio (95% CI) Deep injury 15 (6.0-41) Visible blood on device 6.2 (2.2-21) Procedure involving needle 4.3 (1.7-12) placed in artery or vein Terminal illness in source patient 5.6 (2.0-16) Postexposure use of zidovudine 0.19 (0.06-0.52)

Post Exposure Prophylaxis Issues

Animal Studies of PEP Efficacy Data have been difficult to interpret and extrapolate to humans, but provide encouraging evidence of the effectiveness of PEP Reduced PEP effectiveness if: Large dose of inocula Delay in time to PEP Shortened duration of PEP Decreased dose of PEP

Human Studies of HIV PEP Efficacy Little information on efficacy of PEP in humans Seroconversion infrequent following occupational exposure to HIV-infected blood Study of converters vs nonconverters showed use of zidovudine (ZDV) was associated with an 81% decrease in the risk for HIV infection limitations include a small number of cases, and that cases and controls came from different cohorts (Cardo et al, NEJM 1997;337:1485-90.)

Human Studies of HIV PEP: Prevention of Perinatal Transmission ZDV administered during pregnancy, labor, and delivery reduced transmission by 67% (Connor EM, et al. N Engl J Med 1994;331:1173-80.) Protective effect only partially explained by reduction in maternal viral load Protective effect observed when ZDV given only to newborn within the first 48-72 hours of life (Wade NA, et al. N Engl J Med 1998;339:1409-14.) ( Musoke P, et al. AIDS 1999;13:479-86.) (Guay LA, et al. Lancet 1999;354:795-802.)

Elements of Postexposure Management: HIV Baseline evaluation and testing of exposed person Consideration of treatment when to give what to give pregnancy in exposed Follow-up testing and counseling

Postexposure Management: Baseline HIV Testing of Exposed Person EIA standard test Direct virus assays not recommended p24 antigen PCR for HIV RNA

Initiation of HIV PEP Regard as an urgent medical concern If indicated, start PEP as soon as possible after exposure (hours rather than days) Interval after which PEP is no longer likely to be effective in humans is unknown initiating PEP even days or weeks after an exposure should be considered

Re-evaluation of HIV-Exposed Person Consider re-evaluation of the exposed person within 72 hours additional information about the source person may become available if the source person has a negative HIV antibody test, stop PEP

Important Concepts about HIV PEP Determining which and how many agents to use for PEP Professional judgement should be used based on local knowledge and experience in treating HIV Regimens should be tolerable to the exposed person

Considerations When Using PEP Risk of Transmission PEP Risk of Adverse Effects

Situations Where PEP is Rarely, if Ever, Warranted Intact skin contact with blood and potentially infectious body fluids Exposure to unknown source in populations where HIV prevalence is low Low-risk exposure to unknown source

Situations for Which Expert Consultation for HIV PEP is Advised Resistance of the source virus to antiretroviral agents Known or suspected pregnancy in the exposed person Toxicity of the initial PEP regimen

HIV PEP Considerations in Pregnant Exposed Women General principles pregnancy is not a contraindication for PEP exposed person should make informed decision about PEP Choosing regimen is more complex may exacerbate physiologic changes in pregnancy short/long-term effects on fetus/newborn unknown most data are on zidovudine some drugs contraindicated during pregnancy

Postexposure Management: Follow-up HIV Testing of Exposed Person If source HIV positive, test at 6 weeks, 3 months, 6 months EIA standard test direct virus assays not recommended Extending follow-up to 12 months recommended for HCP who become infected with HCV following exposure to co-infected source optional in other situations

Postexposure Management: HIV Postexposure Counseling Side effects of PEP drugs Signs and symptoms of acute HIV infection fever rash flu-like illness Prevention of secondary transmission sexual abstinence or condom use no blood/tissue donation Transmission and PEP drug risks if breastfeeding No work restriction indicated

Recommendations for Healthcare Facilities Establish a bloodborne pathogen management policy Implement management policies (e.g., training, hepatitis B vaccination, exposure reporting, PEP access, etc.) Establish laboratory capacity for bloodborne virus testing Select and use appropriate PEP regimens

Recommendations for Healthcare Facilities (cont.) Provide access to counseling for exposed personnel Monitor adverse events and seroconversion Monitor exposure management programs (e.g., time between exposure and evaluation, testing of source persons, completion of follow-up)

Conclusion Occupational exposure management is complex Prevention is best hepatitis B immunization avoiding occupational blood exposures

Sources of Additional Information Division of Healthcare Quality Promotion Phone: 800-893-0485 Homepage: http://www.cdc.gov/ncidod/hip/ Hepatitis Hotline Phone: 888-443-7232 Homepage: http://www.cdc.gov/hepatitis Needlestick! Homepage:http://www.needlestick.mednet.ucla.edu

Sources of Additional Information National Institute for Occupational Safety and Health bloodborne pathogens website http://www.cdc.gov/niosh/bbppg.html Occupational Safety and Health Administration bloodborne pathogens website http://www.osha-slc.gov/sltc/bloodbornepathogens/index.html